March 2, 2020
We believe manufacturing plays a critical role in our value chain and ability to develop a new category of medicines.
After receiving our first positive clinical data in our infectious disease portfolio, we began building a dedicated in-house manufacturing facility in Norwood, MA, in expectation of significant ongoing pipeline expansion and the long lead time required to create appropriate infrastructure. At Norwood, our process development (“create”) and manufacturing (“make”) capabilities are co-located which enables us to move more quickly from idea to implementation.
Read about our manufacturing facility and its capabilities in this new white paper, which details how Norwood’s flexibility, along with the integration of technical development and manufacturing, has allowed us to quickly pivot and support exploratory programs that require integration of new capabilities.
We have produced more than 100 clinical batches in Norwood since July 2018. Having all engines under one roof has accelerated our learning. We are harnessing the power of the platform—its digital integration and our end-to-end manufacturing capabilities—and applying the learnings to future batches with an end result of rapidly improving our quality, speed, scale, and cost.
This topic will be discussed further at Moderna’s Manufacturing & Digital Day on Wednesday, March 4.